Ribociclib treatment continues to show survival benefits in postmenopausal breast cancer
Adding ribociclib to fulvestrant conferred a survival benefit of nearly 16 months as a first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, according to key data.
Updated OS results from the Phase 3 MONALEESA-3 study, scheduled to be presented at the ESMO Breast Cancer Congress, included a median follow-up of 5 years in women who received ribociclib ( Kisqali, Novartis) more fulvestrant compared to fulvestrant alone as a first-line endpoint, according to a Novartis press release.
Previous results presented at the 2019 ESMO Congress showed a statistically significant improvement in OS in women treated with ribociclib (median, not achieved vs 40 months; HR=0.72; 95% CI, 0.56 -0.92). The new analysis showed a median OS of 67.6 months in the ribociclib group (n=237) versus 51.8 months in the fulvestrant alone group (n=128), representing a 33% relative reduction in the risk of death (HR=0.67; 95% CI, 0.5-0.89), according to the press release.
Additionally, women who received ribociclib had a longer time to subsequent use of chemotherapy (49.2 months versus 29 months; RR=0.62; 95% CI, 0.48-0.8 ), as well as a higher estimated survival rate at 5 years (56.5 months). % versus 42.1%), the press release said.
A greater proportion of women in the ribociclib group compared to the fulvestrant alone group remained on treatment during the extended follow-up (16.5%, n=39 versus 8.6%, n=11), and the researchers did not observe no new adverse events with the combination.
Dennis J. slammon
“MONALEESA-3 results continue to demonstrate the survival benefit of ribociclib treatment for postmenopausal women with advanced breast cancer,” Dennis J. slammondoctor, PhD, director of clinical/translational research at UCLA Jonsson Comprehensive Cancer Center, said in the press release. “Whether combined with fulvestrant or an aromatase inhibitor as a first-line setting, ribociclib offers oncologists a CDK 4/6 inhibitor with consistent benefit to provide women [hormone receptor-positive]/ HER2-negative advanced breast cancer more quality time, regardless of their disease characteristics. »